

GILEAD SCIENCES INC  
 Form 3  
 November 21, 2016

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

|  |         |                                      |  |  |
|--|---------|--------------------------------------|--|--|
| 1. Name and Address of Reporting Person *  |         | 2. Date of Event Requiring Statement | 3. Issuer Name <b>and</b> Ticker or Trading Symbol |  |
| Â Meyers James R                           |         | (Month/Day/Year)                     | GILEAD SCIENCES INC [GILD]                         |  |
| (Last)                                     | (First) | (Middle)                             | 4. Relationship of Reporting Person(s) to Issuer   | 5. If Amendment, Date Original Filed(Month/Day/Year)                   |
|  |         | 11/10/2016                           |  |  |
| GILEAD SCIENCES, INC.,Â 333 LAKESIDE DRIVE |         |                                      | (Check all applicable)                             |  |
| (Street)                                   |         |                                      | <input type="checkbox"/> Director                  | <input type="checkbox"/> 10% Owner                                     |
|  |         |                                      | <input checked="" type="checkbox"/> Officer        | <input type="checkbox"/> Other   |
|  |         |                                      | (give title below)                                 | (specify below)  |
|  |         |                                      | EVP Worldwide Commercial Ops                       | 6. Individual or Joint/Group Filing(Check Applicable Line)             |
|  |         |                                      |  | <input checked="" type="checkbox"/> Form filed by One Reporting Person |
|  |         |                                      |  | <input type="checkbox"/> Form filed by More than One Reporting Person  |
| FOSTER CITY,Â CAÂ 94404                    |         |                                      |  |  |
| (City)                                     | (State) | (Zip)                                |  |  |

**Table I - Non-Derivative Securities Beneficially Owned**

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|
| Common Stock                    | 6,726   | D  | Â   |
| Common Stock                    | 121,151   | I  | By Trust  |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of | 5. Ownership Form of Derivative | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|---|------------------------------------|---------------------------------|---|
|--|--|---|------------------------------------|---------------------------------|---|

Edgar Filing: GILEAD SCIENCES INC - Form 3

|   | Date Exercisable | Expiration Date | Title        | Amount or Number of Shares | Derivative Security | Security: Direct (D) or Indirect (I) (Instr. 5) |   |
|---|------------------|-----------------|--------------|----------------------------|---------------------|---|---|
| Non-qualified Stock Option (Right to Buy) | Â (3)            | 10/22/2017      | Common Stock | 60,000                     | \$ 21               | D   | Â |
| Non-qualified Stock Option (Right to Buy) | Â (3)            | 01/30/2018      | Common Stock | 100,000                    | \$ 21.575           | D   | Â |
| Non-qualified Stock Option (Right to Buy) | Â (3)            | 01/21/2019      | Common Stock | 60,000                     | \$ 23.6             | D   | Â |
| Non-qualified Stock Option (Right to Buy) | Â (3)            | 07/29/2019      | Common Stock | 60,000                     | \$ 24.905           | D   | Â |
| Non-qualified Stock Option (Right to Buy) | Â (3)            | 01/28/2020      | Common Stock | 53,200                     | \$ 23.755           | D   | Â |
| Non-qualified Stock Option (Right to Buy) | Â (4)            | 01/20/2021      | Common Stock | 67,200                     | \$ 19.085           | D   | Â |
| Non-qualified Stock Option (Right to Buy) | Â (4)            | 01/26/2022      | Common Stock | 48,000                     | \$ 24.295           | D   | Â |
| Non-qualified Stock Option (Right to Buy) | Â (4)            | 02/01/2023      | Common Stock | 34,890                     | \$ 40.56            | D   | Â |
| Non-qualified Stock Option (Right to Buy) | Â (4)            | 02/01/2024      | Common Stock | 25,780                     | \$ 80.65            | D   | Â |
| Non-qualified Stock Option (Right to Buy) | Â (4)            | 02/01/2025      | Common Stock | 17,590                     | \$ 104.83           | D   | Â |
| Non-qualified Stock Option (Right to Buy) | Â (4)            | 02/01/2026      | Common Stock | 17,560                     | \$ 84.05            | D   | Â |
| Non-qualified Stock Option (Right to Buy) | Â (4)            | 08/10/2026      | Common Stock | 15,450                     | \$ 78.9             | D   | Â |
| Restricted Stock Unit                     | Â (2)            | Â (2)           | Common Stock | 9,780                      | \$ (1)              | D   | Â |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |                                |       |
|--|---------------|-----------|--------------------------------|-------|
|  | Director      | 10% Owner | Officer                        | Other |
| Meyers James R<br>GILEAD SCIENCES, INC.<br>333 LAKESIDE DRIVE<br>FOSTER CITY, CA 94404 | Â             | Â         | Â EVP Worldwide Commercial Ops | Â     |

## Signatures

/s/ Marissa Song by Power of Attorney for James R.  
Meyers

11/21/2016

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
- (2) The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.
- (3) The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- (4) The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.